OverviewSuggest Edit

Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. The Company's main product is PROTAC, which degrades and removes disease-causing proteins.

TypePublic
HQNew Haven, US
Websitearvinas.com

Latest Updates

Employees (est.) (Jun 2019)103(+11%)
Job Openings12
Revenue (FY, 2018)$14.3 M(+89%)
Share Price (Jun 2019)$20.3 (+3%)

Key People/Management at Arvinas

Timothy Shannon

Timothy Shannon

CEO
Craig M. Crew

Craig M. Crew

Founder
Show more

Arvinas Office Locations

Arvinas has an office in New Haven
New Haven, US (HQ)
5 Science Park
Show all (1)

Arvinas Financials and Metrics

Arvinas Revenue

Arvinas's revenue was reported to be $14.32 m in FY, 2018
USD

Revenue (Q2, 2019)

4.0m

Net income (Q2, 2019)

(17.2m)

EBIT (Q2, 2019)

(18.4m)

Market capitalization (10-Jun-2019)

654.9m

Closing stock price (10-Jun-2019)

20.3

Cash (30-Jun-2019)

11.3m

EV

645.7m
Arvinas's current market capitalization is $654.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

6.7m7.6m14.3m

Revenue growth, %

14%

General and administrative expense

3.2m3.5m12.9m

R&D expense

19.9m28.8m45.2m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019

Revenue

1.7m3.4m4.0m4.0m

General and administrative expense

857.3k4.3m5.6m6.4m

R&D expense

7.2m13.1m14.2m16.0m

Operating expense total

8.1m17.4m19.8m22.4m
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

5.1m30.9m3.2m

Accounts Receivable

25.0m

Prepaid Expenses

1.4m316.9k

Current Assets

37.3m65.5m195.7m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019

Cash

6.2m28.8m11.3m

Prepaid Expenses

3.5m

Current Assets

95.5m179.7m163.3m

PP&E

3.3m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(14.4m)(24.0m)(41.5m)

Depreciation and Amortization

436.3k347.4k706.0k

Accounts Payable

1.2m(969.5k)2.0m

Cash From Operating Activities

(19.4m)5.1m(16.1m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019

Net Income

(19.3m)(25.4m)(14.4m)(31.6m)

Depreciation and Amortization

246.4k483.1k246.2k556.6k

Accounts Payable

(648.0k)704.2k(1.7m)(1.4m)

Cash From Operating Activities

(23.0m)(3.9m)(12.7m)(26.3m)
USDY, 2019

EV/EBIT

-44.6 x

EV/CFO

-31.2 x

Revenue/Employee

39.0k

Financial Leverage

1.5 x
Show all financial metrics

Arvinas Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Arvinas Androgen Receptor
Arvinas BRD4
Arvinas Estrogen Receptor
Arvinas Winchester

Arvinas Online and Social Media Presence

Embed Graph

Arvinas News and Updates

Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants

Agreement worth more than USD 110 million includes the first-ever research application of Proteolysis-Targeting Chimera (PROTAC®) technology in agriculture / Bayer and Arvinas to launch joint venture to develop targeted protein degraders for agriculture applications / Collaboration agreement and equ…

Arvinas Reports First Quarter Financial Results and Provides Corporate Update

Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC® Protein Degrader, ARV-110 Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC® Protein Degrader, ARV-110

Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Recently Announced the Initiation of Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC™ Protein Degrader ARV-110 Recently Announced the Initiation of Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC™ Protein Degrader ARV-110

Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium

Company to Highlight ARV-110 PROTAC™ Protein Degrader for the Treatment of Prostate Cancer Company to Highlight ARV-110 PROTAC™ Protein Degrader for the Treatment of Prostate Cancer

Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer

Expects Enrollment of Phase 1 Trial to Begin in the First Quarter of 2019 Expects Enrollment of Phase 1 Trial to Begin in the First Quarter of 2019

Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination
Show more

Arvinas Blogs

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader Content Import Tue, 08/27/2019 - 07:01 Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, a…

Arvinas To Present at the Wedbush PacGrow Healthcare Conference

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday,

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEW HAVEN, Conn. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arvinas , Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter of 2019 and provided a corporate update.

Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer

Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer Content Import Mon, 07/29/2019 - 07:01 Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer July 29, 2019 at 7:00 AM EDT This release is a backfill from a News Wire General …

Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk

Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk Content Import Thu, 07/25/2019 - 07:01 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk July 25, 2019 at 7:00 AM EDT This release is a backfill from a News Wire …

Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference

Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference Content Import Thu, 07/18/2019 - 07:01 Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference…
Show more

Arvinas Frequently Asked Questions

  • Who are Arvinas key executives?

    Arvinas's key executives are Timothy Shannon and Craig M. Crew.

  • How many employees does Arvinas have?

    Arvinas has 103 employees.

  • What is Arvinas revenue?

    Latest Arvinas annual revenue is $14.3 m.

  • What is Arvinas revenue per employee?

    Latest Arvinas revenue per employee is $139.1 k.

  • Who are Arvinas competitors?

    Competitors of Arvinas include Actuate Therapeutics, Vor Biopharma and Agenus.

  • Where is Arvinas headquarters?

    Arvinas headquarters is located at 5 Science Park, New Haven.

  • Where are Arvinas offices?

    Arvinas has an office in New Haven.

  • How many offices does Arvinas have?

    Arvinas has 1 office.